tetano
Editor, Senior Moderator
Cell Rep
. 2022 Aug 15;111299.
doi: 10.1016/j.celrep.2022.111299. Online ahead of print.
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
Alexandra C Walls[SUP] 1 [/SUP], Laura A VanBlargan[SUP] 2 [/SUP], Kai Wu[SUP] 3 [/SUP], Angela Choi[SUP] 3 [/SUP], Mary Jane Navarro[SUP] 4 [/SUP], Diana Lee[SUP] 3 [/SUP], Laura Avena[SUP] 3 [/SUP], Daniela Montes Berrueta[SUP] 3 [/SUP], Minh N Pham[SUP] 5 [/SUP], Sayda Elbashir[SUP] 3 [/SUP], John C Kraft[SUP] 5 [/SUP], Marcos C Miranda[SUP] 5 [/SUP], Elizabeth Kepl[SUP] 5 [/SUP], Max Johnson[SUP] 5 [/SUP], Alyssa Blackstone[SUP] 5 [/SUP], Kaitlin Sprouse[SUP] 4 [/SUP], Brooke Fiala[SUP] 5 [/SUP], Megan A O'Connor[SUP] 6 [/SUP], Natalie Brunette[SUP] 5 [/SUP], Prabhu S Arunachalam[SUP] 7 [/SUP], Lisa Shirreff[SUP] 8 [/SUP], Kenneth Rogers[SUP] 8 [/SUP], Lauren Carter[SUP] 5 [/SUP], Deborah H Fuller[SUP] 6 [/SUP], Francois Villinger[SUP] 8 [/SUP], Bali Pulendran[SUP] 7 [/SUP], Michael S Diamond[SUP] 9 [/SUP], Darin K Edwards[SUP] 3 [/SUP], Neil P King[SUP] 5 [/SUP], David Veesler[SUP] 10 [/SUP]
Affiliations
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses against emerging SARS-CoV-2 variants of concern (VOCs) in real time is key to inform public health policies. Serum neutralizing antibody titers are the current best correlate of protection from SARS-CoV-2 challenge in non-human primates and a key metric to understand immune evasion of VOCs. We report that vaccinated BALB/c mice do not recapitulate faithfully the breadth and potency of neutralizing antibody responses elicited by various vaccine platforms against VOCs, compared with non-human primates or humans, suggesting caution should be exercised when interpreting data obtained with this animal model.
Keywords: COVID-19; CP: Immunology; CP: Microbiology; SARS-CoV-2; antibodies; humans; mouse; non-human primates; vaccines.
. 2022 Aug 15;111299.
doi: 10.1016/j.celrep.2022.111299. Online ahead of print.
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
Alexandra C Walls[SUP] 1 [/SUP], Laura A VanBlargan[SUP] 2 [/SUP], Kai Wu[SUP] 3 [/SUP], Angela Choi[SUP] 3 [/SUP], Mary Jane Navarro[SUP] 4 [/SUP], Diana Lee[SUP] 3 [/SUP], Laura Avena[SUP] 3 [/SUP], Daniela Montes Berrueta[SUP] 3 [/SUP], Minh N Pham[SUP] 5 [/SUP], Sayda Elbashir[SUP] 3 [/SUP], John C Kraft[SUP] 5 [/SUP], Marcos C Miranda[SUP] 5 [/SUP], Elizabeth Kepl[SUP] 5 [/SUP], Max Johnson[SUP] 5 [/SUP], Alyssa Blackstone[SUP] 5 [/SUP], Kaitlin Sprouse[SUP] 4 [/SUP], Brooke Fiala[SUP] 5 [/SUP], Megan A O'Connor[SUP] 6 [/SUP], Natalie Brunette[SUP] 5 [/SUP], Prabhu S Arunachalam[SUP] 7 [/SUP], Lisa Shirreff[SUP] 8 [/SUP], Kenneth Rogers[SUP] 8 [/SUP], Lauren Carter[SUP] 5 [/SUP], Deborah H Fuller[SUP] 6 [/SUP], Francois Villinger[SUP] 8 [/SUP], Bali Pulendran[SUP] 7 [/SUP], Michael S Diamond[SUP] 9 [/SUP], Darin K Edwards[SUP] 3 [/SUP], Neil P King[SUP] 5 [/SUP], David Veesler[SUP] 10 [/SUP]
Affiliations
- PMID: 35988541
- DOI: 10.1016/j.celrep.2022.111299
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses against emerging SARS-CoV-2 variants of concern (VOCs) in real time is key to inform public health policies. Serum neutralizing antibody titers are the current best correlate of protection from SARS-CoV-2 challenge in non-human primates and a key metric to understand immune evasion of VOCs. We report that vaccinated BALB/c mice do not recapitulate faithfully the breadth and potency of neutralizing antibody responses elicited by various vaccine platforms against VOCs, compared with non-human primates or humans, suggesting caution should be exercised when interpreting data obtained with this animal model.
Keywords: COVID-19; CP: Immunology; CP: Microbiology; SARS-CoV-2; antibodies; humans; mouse; non-human primates; vaccines.